MiMedx Group, Inc.

NASDAQ:MDXG

Biotechnology

Healthcare
$3.18 +2.22%

+$0.08 today

Market cap
$464.04M
Beta
1.46
P/E (TTM)
17.8
EPS (TTM)
$0.21
52W Low $3.03High $7.99

Volume 1.51M

Average 1.55M

MDXG Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

MiMedx Group, Inc.NASDAQ: MDXG

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue dips below year-ago levels

Q1 FY2026 revenue of $58.99M fell 33.1% year over year, behind the +10.5% change in trailing-twelve-month revenue. Sequentially, it fell 50.0% from the prior quarter. Over 3 fiscal years it compounded at +16.1% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 3 analysts of $251.76M (-39.9%) for the fiscal year ending Dec 2026, a slowdown from the +20.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$58.99M-50.0% QoQ
Last fiscal yearDec 2025
$418.63M+20.0% YoY
LTMMar 2026
$389.42M+10.5% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.1%-35.6%-2.5 pp
1 year+20.0%-39.9%-59.9 pp
3-year CAGR+16.1%-4.9%-20.9 pp
5-year CAGR+0.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
418.63M USD
Year-over-year change
+20.0%
4-year CAGR
+14.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How MDXG compares with its peers on the latest reported figures

  • MDXG's LTM Mar 2026 revenue of $389.42M is the 2nd highest of the 8 companies compared; the peer median is $26.55M.
  • Its year-over-year change of +10.5% is the 4th highest of 8, against a peer median of +1.0%.
  • Over three fiscal years its annual growth of +16.1% compares with a peer median of +13.9%.
MDXG Competitors Peer median
Revenue for MDXG and competitors
Company Period LTM YoY 3-year CAGR
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$513.57M +11.9%+7.7%
MDXGMiMedx Group, Inc.LTM Mar 2026$389.42M +10.5%+16.1%
SMTISanara MedTech Inc.LTM Mar 2026$107.51M +17.4%+31.0%
RCELAVITA Medical, Inc.LTM Mar 2026$72.35M +1.0%+27.7%
CELUCelularity Inc.LTM Dec 2025$26.55M -51.0%+13.9%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$14.78M +54.6%-0.3%
MDWDMediWound Ltd.LTM Mar 2026$14.48M -24.6%-13.8%
BSEMBioStem Technologies, Inc.LTM Jun 2026-$60.31M -119.6%+90.4%
Peer median (excluding MDXG) $26.55M+1.0%+13.9%

Competitors are the stored peer set for MDXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue242.02M267.84M321.48M348.88M418.63M
Cost of Revenue39.63M48.32M54.63M60.07M73.01M
Gross Profit202.39M219.53M266.84M288.81M345.62M
Gross Margin83.6%82.0%83.0%82.8%82.6%
Research & Development9.93M12.7M12.67M12.34M15.1M
Selling, General & Admin194.85M220.85M216.3M216.39M266.19M
Operating Expenses209.44M234.25M229.73M229.94M281.29M
Depreciation & Amortization5.18M4.05M3.43M6.04M14.88M
EBITDA(1.89M)(10.69M)40.52M65.35M82.93M
EBITDA Margin-0.8%-4.0%12.6%18.7%19.8%
Operating Income(7.05M)(14.73M)37.12M58.87M63.89M
Operating Margin-2.9%-5.5%11.5%16.9%15.3%
Interest Income00004.72M
Interest Expense4.98M5.02M6.46M1.01M1.78M
Other Income / Expenses(5M)(5.02M)(6.48M)(1.57M)2.38M
Income Before Tax(12.05M)(19.75M)30.63M57.29M66.26M
Pre-Tax Margin-5.0%-7.4%9.5%16.4%15.8%
Income Tax Expense247K206K(36.81M)15.3M17.68M
Net Income(12.3M)(30.2M)67.44M42.42M48.58M
Net Margin-5.1%-11.3%21.0%12.2%11.6%
EPS (Basic)(0.09)(0.27)0.480.290.33
EPS (Diluted)(0.09)(0.27)0.380.280.32
Weighted Avg Shares110.35M112.91M116.5M146.98M147.79M
Weighted Avg Shares (Diluted)110.35M112.91M145.96M149.05M149.72M

MiMedx Group, Inc.

NASDAQ:MDXG

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.